CMS Ventures, launched in 2020, is the investment arm of China Medical System Holdings Limited (CMS), a well-established, innovation-driven specialty pharma founded in 1995, and listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 867). CMS Ventures receives supports from AstraZeneca and Cambridge Judge Business School. CMS Ventures provide patient capital for ambitious Biotech and Life Sciences start-ups in the 4Ds (Drugs, Devices, Diagnostics and Digital), interested in entering the Chinese market with a trusted partner of choice.